Tag: sequencing technology

Illumina to Pay $1.2 Billion to Acquire Pacific Biosciences

IT’S AN ACQUISITION THAT BRINGS TOGETHER two different gene sequencing technologies into one firm. On Nov. 1, Illumina, Inc., announced an agreement to acquire Pacific Biosciences (PacBio) for $1.2 billion.

This deal will bolster Illumina’s already-dominant position in the market for DNA-sequencing machines. Wall Street analysts quickly pointed out that this gives Illumina control of two gene

View Article

March 26, 2018 Intelligence: Late Breaking Lab News

Intelligence Late & Latent News

On March 6, one of the lab industry’s long-serving executives and consultants, Jack Mattice, PhD, of Vancouver, Wash., died from flu complications. He was 77 years old. Mattice earned a PhD in medical microbiology from University of Oregon. Within a few years, he was handling market development for United Medical Laboratories (UML), of Portland, Ore. UML reached

View Article

Whole Genome Sequencing Is Poised for Clinical Use

CEO SUMMARY: Pathologists and clinical lab managers interested in following the advances in use of whole human genome sequencing for clinical purposes should follow the money. Within weeks of obtaining FDA clearance for its MiSeqDx system and reagents, Illumina had inked major agreements with Quest Diagnostics Incorporated and Laboratory Corporation of America. Both national lab

View Article

September 17, 2012 “Intelligence: Late Breaking Lab News”

Exome sequencing testing for cancer patients is now offered by the Cancer Genetics Laboratory at Baylor College of Medicine (BCM) in Houston, Texas. This clinical testing will be performed using next-generation gene sequencing technology. Pathologists at Baylor are among the first in the nation to offer exome-based testing services. “Cancer exome sequencing is poised to

View Article

Exome Sequencing Next “Big Thing” for Diagnosis

CEO SUMMARY: For disease diagnostics, exome sequencing is not yet routine, but geneticists are getting close. Using this technology, researchers read those parts of the human genome where about 85% of disease-causing mutations reside. By looking only at the regions that encode proteins—the workhorse machinery of the cell—researchers identify dis- ease causes much faster than

View Article

Whole Genome Sequencing: Is It Ready for Prime Time?

CEO Summary: Pathologists at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in a collaboration with GenomeQuest, Inc., will produce whole human genome sequences of patient tumors and other specimens. These whole genome sequences will be studied to learn what diagnostic, therapeutic, and prognostic information they contain. GenomeQuest CEO Richard Resnick discusses what is required

View Article

October 16, 2006 “Intelligence: Late Breaking Lab News”

American Esoteric Laboratories, Inc. today announced that it has signed an extended, five-year contract to provide reference and esoteric testing services to the 14-hospital Baptist Memorial Health Care Corporation (BMHCC) in Memphis, Tennessee. This relationship was developed as part of AEL’s acquisition of Memphis Pathology Laboratories in 2004.
NEW & STEPHANELLI LAUNCH AP COMPANY
Today, Aurora Diagnostics,

View Article